ATMOS, A Proof-of-Concept Trial of Inhaled Mosliciguat, A First-in-Class Soluble Guanylate Cyclase Activator – A Novel Approach to Address Unmet Needs in PH
Hossein Ardeschir Ghofrani(Justus-Liebig-Universität Gießen), Grzegorz Kopeć(John Paul II Hospital), Johannes Nagelschmitz(University of Wuppertal), Hikmet Al Hiti(Institute of Clinical and Experimental Medicine), Michael Halank(University Hospital Carl Gustav Carus), Pavel Jansa(General University Hospital in Prague), Sylvia Nikkho(MerLion Pharma (Germany)), Sandra Ligges(University of Münster), HH Leuchte(Ludwig-Maximilians-Universität München), Dooyoung Jung(SK Group (United States)), Paula Vesterinen(Ferring Pharmaceuticals (Finland)), Horst Olschewski(Sigmund Freud Privatuniversität Wien), Khodr Tello(Universities of Giessen and Marburg Lung Center), Tobias J. Lange(University Hospital Regensburg), Sudhir Penugonda(ClearMotion (United States)), E. Becker(Bayer (Germany)), Markus Woischnik(University of Wuppertal), Sheima T. Saleh(Bayer (Germany))
American Journal of Respiratory and Critical Care Medicine
May 1, 2025
Cited by 1
Related Papers
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
Inhaled Iloprost for Severe Pulmonary Hypertension
|New England Journal of Medicine|2002|1.8k
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
|New England Journal of Medicine|2013|1.4k
Mechanisms of disease: pulmonary arterial hypertension
|Nature Reviews Cardiology|2011|784
Pulmonary hypertension in chronic lung disease and hypoxia
|European Respiratory Journal|2018|777